Janssen debuts schizophrenia awareness doc

Share this article:
Janssen debuts schizophrenia awareness doc
Janssen debuts schizophrenia awareness doc
Johnson & Johnson is back in the film game with Janssen's half-hour documentary Living with Schizophrenia: A Call for Hope and Recovery.

The unbranded film, which follows several young people with schizophrenia and their families, aims to lessen the fear and stigma associated with the condition. It debuted Friday in Washington, DC, and will be distributed through a series of community-based events, via advocacy groups and online at hopeandrecoveryfilm.com.

The film, said director Emily Abt, “highlights the stories that don't make the headlines – the stories of hope and promise.” Abt's grandmother struggled with schizophrenia.

Janssen's Risperdal and Invega franchises are indicated for the treatment of schizophrenia, and the company sponsored an earlier documentary on the topic. In 2007, J&J's Centocor unit sponsored “Innerstate” an hour-long documentary following a similar formula, following several young people struggling with autoimmune disorders. Centocor makes Remicade for rheumatoid arthritis, psoriasis and Crohn's Disease.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...